Results 1 to 10 of about 8,933 (160)
Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production [PDF]
Cells, 2021 Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. While the use of this reagent has been associated with an increased risk of gastrointestinal bleeding,
Hiromi Kurokawa +3 more
doaj +3 more sources
Pharmacokinetics and Pharmacogenetics of Dabigatran [PDF]
Рациональная фармакотерапия в кардиологии, 2021 Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. V. Savinova +4 more
doaj +3 more sources
Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions [PDF]
Pharmacology Research & Perspectives, 2020 To assess bioequivalence of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions. This was an open‐label, single‐center, randomized four‐period crossover study with a 7‐day washout period. A single oral dose
Xin Li +9 more
doaj +2 more sources
Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation [PDF]
TH Open, 2019 Background Dabigatran etexilate has become widely used for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). Currently, there is limited information in real-world patients relating to dabigatran etexilate exposure and ...
Bryan H. Simpson +3 more
doaj +2 more sources
Pharmaceuticals, 2023 Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung +5 more
doaj +2 more sources
The Discovery of Dabigatran Etexilate [PDF]
Frontiers in Pharmacology, 2013 Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is caused by an excessive stimulation of coagulation.
Joanne evan Ryn +6 more
doaj +2 more sources
Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia
Life, 2022 Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair +5 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim.
Yu. B. Belousov +3 more
doaj +3 more sources
European Journal of Case Reports in Internal Medicine, 2017 Objective: To describe the benefits of reversal of the anticoagulation effects of dabigatran etexilate in patients requiring urgent surgery or thrombolysis for ischaemic stroke. Materials and methods: Four patients, treated with dabigatran etexilate and
Fredrik Andreas von Wowern +2 more
doaj +1 more source
Determination of Dabigatran Concentration in Human Plasma and Breast Milk
International Journal of Analytical Chemistry, 2021 Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick +4 more
doaj +1 more source